- Home
- VNOM vs SRRK Comparison
VNOM vs SRRK Comparison
Compare VNOM & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VNOM | SRRK |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 6.8B |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VNOM | SRRK |
|---|---|---|
| Price | $45.31 | $49.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $54.85 | ★ $56.17 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $1,395,000,000.00 | N/A |
| Revenue This Year | $69.89 | N/A |
| Revenue Next Year | N/A | $534.24 |
| P/E Ratio | $85.23 | ★ N/A |
| Revenue Growth | ★ 62.02 | N/A |
| 52 Week Low | $35.10 | $27.07 |
| 52 Week High | $51.13 | $58.49 |
Technical Indicators
Market Signals| Indicator | VNOM | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 64.66 | 38.97 |
| Support Level | $44.38 | $44.08 |
| Resistance Level | $47.83 | $48.23 |
| Average True Range (ATR) | 0.88 | 2.34 |
| MACD | 0.52 | -1.04 |
| Stochastic Oscillator | 97.89 | 8.20 |
Price Performance
Historical ComparisonAbout VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.